OZEMPIC

Jul 10, 2026

Summary The obesity treatment market has shifted from a niche category to a major pharma growth engine, with revenues in the leading markets rising from about $16 billion in 2025 to a projected $80 billion by 2034 and potentially more than $100 billion by 2036. Eli Lilly led the category in 2025, driven by M...

Feb 03, 2025

The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease. The approval for chr...

Sep 27, 2024

On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 partic...